



GLOBAL HEPATITIS SUMMIT 2025

LOS ANGELES
USA
MARCH 18 – 21, 2025

Tuesday, March 18, 2025

- 5:00 PM - 6:30 PM
- PLENARY 1 - A Focus On Where We are At
- Opening remarks **John Ward and Norah Terrault**
 - Bridging basic-clinical-implementation spheres in viral hepatitis + Q&A **Jordan Feld**
 - Global progress on hepatitis B, C, and D elimination + Q&A **Meg Doherty**
 - PANEL: Advocacy - coalitions that led to national commitment to elimination

Wednesday, March 19, 2025

8:30 AM - 10:00 AM	<p>CLINICAL PARALLEL 1 - Management of HBV in 2025</p> <ul style="list-style-type: none"> • Interferon as a Component of HBV Cure in 2024 and 2034 Harry Janssen • Invited Talk • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	<p>BASIC PARALLEL 1 - HCV virology: replicating success</p> <ul style="list-style-type: none"> • What can we learn from HCV for the other hepatitis viruses? Ralf Bartenschlager • Pharmacology of long-acting HCV therapeutics Andrew Owen • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	<p>PUBLIC HEALTH PARALLEL 1 - Interventions to prevent viral hepatitis</p> <ul style="list-style-type: none"> • Prevention of hepatitis B and D (including PMTCT-increasing HBV birth dose, novel strategies to treat any woman HbsAg+ if no HBV DNA or birth dose available) Ben Cowie • Prevention of hepatitis C (focus on PWID – known interventions that are effective, such as opioid agonist treatment and syringe service programs) Julie Bruneau • Oral Presentation • Oral Presentation • Oral Presentation <p>Oral Presentation Q&A</p>	<p>CLINICAL PARALLEL 2 - Practical Strategies for implementing Guidelines and Maximizing Treatment Outcomes</p> <ul style="list-style-type: none"> • How to Engage and Support Priority Populations for Viral Hepatitis Care in Non-Endemic Regions Christine Greenway • Development and Expansion of Novel Care Models for a Global Population • Patient and Provider Perspective on Overcoming Barriers to Care Su Wang • Oral Presentation • Oral Presentation • Q&A
--------------------	--	---	---	---

- 10:30 AM - 12:00 PM
- PLENARY 2 - State of the Art: Report Card on Drug Development for HBV: Lessons Learned and the Path Forward
- Report Card on Drug Development for HBV: Lessons Learned and the Path Forward + Q&A **Ed Gane**
 - Oral Presentation + Q&A
 - Oral Presentation + Q&A
 - Introductory Talk
 - Panel - HBV Therapeutics (what's needed now and in the future) + Q&A

1:30 PM - 3:00 PM	<p>BASIC PARALLEL 2 - MishMASH: molecular mechanisms for liver disease</p> <ul style="list-style-type: none"> MASH: molecular underpinnings of novel therapeutics Percy Knolle Inflammatory premise for cancer Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>CLINICAL PARALLEL 3 - ILCA-GHS HCC Symposium</p> <ul style="list-style-type: none"> Risk stratification – HBV and post-SVR Debate – Are there patients that we can stop surveillance in low risk patients? Neil Mehta Early detection/screening – surveillance underuse and emerging modalities Ju Dong Yang Panel – implementation of these strategies Neil Mehta; Ju Dong Yang 	<p>PUBLIC HEALTH PARALLEL 2 - Screening and diagnosis of viral hepatitis (Identifying the right test, for the right patient, in the right setting)</p> <ul style="list-style-type: none"> Optimising strategies to enhance screening and diagnosis for hepatitis B Jean-Michel Pawlowsky Optimising strategies to enhance screening and diagnosis for hepatitis C (lab-based testing, point-of-care testing, dried-blood spot testing, self-testing) Nathan Furukawa Oral Presentation Oral Presentation Oral Presentation Oral Presentation <p>Q&A</p>
3:30 PM - 5:00 PM	<p>CLINICAL PARALLEL 5 - Delta Therapies -- Current and Future</p> <ul style="list-style-type: none"> Overview of New Drug Development for Hepatitis Delta Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta Maria Buti Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>PUBLIC HEALTH PARALLEL 3 - Interventions to enhance testing, treatment, and viral elimination</p> <ul style="list-style-type: none"> Interventions to enhance linkage to hepatitis C care and treatment (not diagnostic strategies - e.g. electronic medical record audit, financial incentives, peer support, pharmacy starter packs) Seun Falade-Nwulia Interventions to enhance linkage to hepatitis B & D care and treatment (not diagnostic strategies) Alexander Stockdale Oral Presentation Oral Presentation Oral Presentation Oral Presentation <p>Q&A</p>	<p>CLINICAL PARALLEL 4 - Optimizing HBV Treatment: Propects for a functional cure</p> <ul style="list-style-type: none"> Progress towards a Sterilizing Cure - Advances in Gene editing and Targeting cccDNA Fabien Zoulim The Role of RNA interference (siRNA, ASO) as the backbone of HBV Cure strategies Kosh Agarwal Invited Talk Oral Presentation Oral Presentation Q&A

Thursday, March 20, 2025

8:30 AM - 10:00 AM	<p>CLINICAL PARALLEL 6 - HBV Treatment Challenges and Controversies</p> <ul style="list-style-type: none"> Do Not Stop Long-Term NA Therapy in Absence of Functional Cure (against) Anna Lok You Can Stop Long-Term Therapy in Absence of Functional Cure (for) What is the Evidence for Expanding NA Therapy Patrick Kennedy Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>PUBLIC HEALTH PARALLEL 4 - Special Populations</p> <ul style="list-style-type: none"> Corrections/Jails Addressing Challenges to Engage People who Use Drugs into Care - A Community Perspective Sione Crawford Overseas born/refugees/migrants - Overview Nasra Giama Collaborating with First Nations Communities to Enhance Hepatitis C Care Kate Dunn Q&A 	<p>BASIC PARALLEL 3 - "Dueling" virology: HBV and HDV</p> <ul style="list-style-type: none"> Molecular basis for an HBV cure using antivirals Chloe Thio From controlling HDV to HDV cure Marc Ghany Oral Presentation Oral Presentation Oral Presentation Q&A
10:30 AM - 12:00 PM	<p>PLENARY 3 - State of the Art: Thinking outside the Box for HCV: Treat to Cure and Eliminate</p> <ul style="list-style-type: none"> Thinking outside the Box for HCV: Treat to Cure and Eliminate + Q&A Margaret Hellard Oral Presentation + Q&A Oral Presentation + Q&A Introductory Talk Panel + Q&A 		

1:30 PM - 3:00 PM	<p>CLINICAL PARALLEL 7 - New Diagnostics and Technologies in Liver Disease - Potential for Current and Future Clinical Practice</p> <ul style="list-style-type: none"> Novel Biomarkers and Point of Care Tests for HBV management Application of Artificial Intelligence in Viral Hepatitis Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>BASIC PARALLEL 4 - Exploiting adaptive immunity to combat viral hepatitis</p> <ul style="list-style-type: none"> Restoring immunity to cure hepatitis B Ulrike Protzer Immunologic prescription for a vaccine to prevent chronic hepatitis C Andrea Cox Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>PUBLIC HEALTH PARALLEL 5 - Hepatitis B, C, D elimination</p> <ul style="list-style-type: none"> Novel Interventions to Facilitate Hep C Elimination in Rural Settings (Integrating work on larger scale, randomized control trials, rural home test kits) Jennifer Havens Addressing Barriers to Hepatitis B Screening in Low and Middle Income Settings Tanwadee Tawasek Oral Presentation Oral Presentation Oral Presentation Oral Presentation <p>Q&A</p>
3:30 PM - 5:00 PM	<p>CLINICAL PARALLEL 8 - Overlapping Epidemics: Viral Hepatitis Meets Steatotic Liver Disease</p> <ul style="list-style-type: none"> Alcohol and Viral Hepatitis: How Much is too Much? Jennifer Fleming Risk of HCC in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Viral Hepatitis Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>PUBLIC HEALTH PARALLEL 6 - Pathways towards Hepatitis Elimination (Partial WHO Session)</p> <ul style="list-style-type: none"> WHO Progress, and Next Steps toward hepatitis elimination Funmi Lesi Spain Javier Garcia-Samaniego South Korea Pakistan Saeed Hamid Plans, policies and progress toward hepatitis elimination: Findings from 33 national profiles Lindsey Hiebert Q&A 	
3:30 PM - 5:30 PM	<p>CLINICAL PARALLEL 9 - Remaining Challenges in Hepatitis C</p> <ul style="list-style-type: none"> HCV : Improving care after HCV diagnosis and after HCV Cure Jennifer Price Treatment of HCV in Context of HCC - Remaining Challenges in 2025 Oral Presentation Oral Presentation Oral Presentation Q&A 		
Friday, March 21, 2025			
8:30 AM - 10:00 AM	<p>CLINICAL PARALLEL 10 - Special Populations in Viral Hepatitis</p> <ul style="list-style-type: none"> Immunocompromised Patients and Viral Hepatitis Management Management of Children with Viral Hepatitis (i.e., Immuntolerant or High Replicative, Non-Inflammatory) Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>BASIC PARALLEL 5 - Gene- and Cell therapies - latest news</p> <ul style="list-style-type: none"> CAR-T cells in liver transplantation Elmar Jaeckel Gene correction in the liver using CRISPR Alexander Ploss Oral Presentation Oral Presentation Oral Presentation Q&A 	<p>PUBLIC HEALTH PARALLEL 7 - Panel Discussion: Innovations to Accelerate Hepatitis Elimination</p> <ul style="list-style-type: none"> The Role of Policy Development in the Access to New Prevention Screening & Treatment Carolyn Wester How to Implement New Diagnostic Technologies in the Field Boatema Ntiri-Reid Access to the Latest Therapies Mila Maistat The Roles of Communities of Practice: To Implement New Technologies & Strategies Sanjeev Arora Panel Discussion + Q&A
10:30 AM - 12:00 PM	<p>PLENARY 4 - State of the Art: Towards Achieving Health Equity</p> <ul style="list-style-type: none"> Australia Greg Dore UK Spain Camila Picchio Africa Ponsiano Ocama Brazil Thor Dantas China Panel + Q&A 		
Time Zone: (UTC-08:00) Pacific Time (US & Canada) [Change Time Zone]			